Trial Profile

A phase I clinical trial assessing ATI-1701

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 20 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Mar 2025 According to Appili Therapeutics media release, Without additional funding, company does not expect to be in a position to submit an Investigational New Drug Application for ATI-1701 to the U.S. Food and Drug Administration by the end of this year, as originally expected.
13 Aug 2024 According to Appili Therapeutics media release, the company expects an IND submission in 2025.
25 Jul 2024 According to Appili Therapeutics media release, ATI-1701 has been awarded a total of US$14 million in U.S. Air Force Academy commitments, facilitating essential activities like manufacturing, non-clinical studies, and regulatory activities for an Investigational New Drug (IND) application.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com